BG64278B1 - 2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван... - Google Patents

2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван... Download PDF

Info

Publication number
BG64278B1
BG64278B1 BG103220A BG10322099A BG64278B1 BG 64278 B1 BG64278 B1 BG 64278B1 BG 103220 A BG103220 A BG 103220A BG 10322099 A BG10322099 A BG 10322099A BG 64278 B1 BG64278 B1 BG 64278B1
Authority
BG
Bulgaria
Prior art keywords
alkyl
substituted
formula
hydrogen
aryl
Prior art date
Application number
BG103220A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103220A (en
Inventor
Eddy J. Freyne
Francisco J. Fernandez-Gadea
Jose I. Andres-Gil
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG103220A publication Critical patent/BG103220A/xx
Publication of BG64278B1 publication Critical patent/BG64278B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG103220A 1996-10-02 1999-03-01 2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван... BG64278B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02
PCT/EP1997/005322 WO1998014432A1 (fr) 1996-10-02 1997-09-24 Derives de 2-cyanoiminoimidazole inhibant la phosphodiesterase iv

Publications (2)

Publication Number Publication Date
BG103220A BG103220A (en) 1999-11-30
BG64278B1 true BG64278B1 (bg) 2004-08-31

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103220A BG64278B1 (bg) 1996-10-02 1999-03-01 2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван...

Country Status (30)

Country Link
US (1) US6051718A (fr)
EP (1) EP0934280B1 (fr)
JP (1) JP3068208B2 (fr)
KR (1) KR100520002B1 (fr)
CN (1) CN1106387C (fr)
AR (1) AR008875A1 (fr)
AT (1) ATE236884T1 (fr)
AU (1) AU719561B2 (fr)
BG (1) BG64278B1 (fr)
BR (1) BR9712256B1 (fr)
CA (1) CA2267322C (fr)
CY (1) CY2380B1 (fr)
CZ (1) CZ297474B6 (fr)
DE (1) DE69720757T2 (fr)
DK (1) DK0934280T3 (fr)
EE (1) EE03825B1 (fr)
ES (1) ES2196308T3 (fr)
HU (1) HU225158B1 (fr)
IL (2) IL129298A0 (fr)
MY (1) MY116980A (fr)
NO (1) NO312960B1 (fr)
NZ (1) NZ334971A (fr)
PL (1) PL194673B1 (fr)
PT (1) PT934280E (fr)
RU (1) RU2180902C2 (fr)
SI (1) SI0934280T1 (fr)
SK (1) SK285878B6 (fr)
TR (1) TR199900732T2 (fr)
UA (1) UA62939C2 (fr)
WO (1) WO1998014432A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284468B6 (sk) 1998-04-01 2005-04-01 Janssen Pharmaceutica N. V. Pyridínový derivát, spôsob jeho prípravy a použitie, kompozícia s jeho obsahom a spôsob jej prípravy
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7476688B2 (en) 2001-04-19 2009-01-13 Eisai R&D Management Co., Ltd. Cyclic amidine derivatives
WO2002094320A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions therapeutiques permettant de reparer la chondropathie
DE60234031D1 (de) * 2001-07-11 2009-11-26 Nikken Chemicals Co Ltd Mittel zur behandlung allergischer augenerkrankungen
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
DK1463493T3 (da) 2001-12-14 2008-02-04 Serono Lab Fremgangsmåder til at inducere æglösning ved anvendelse af en ikke polypeptid-cAMP-niveaumodulator
JP4549970B2 (ja) 2003-02-19 2010-09-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 環状ベンズアミジン誘導体の製造方法
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
CA2875964C (fr) * 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Inhibiteurs de seca et leurs procedes de fabrication et d'utilisation
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
ES2227519T3 (es) * 1992-07-28 2005-04-01 Aventis Pharma Limited Inhibidores de c-amp-fosfodiesterasa.
BR9307570A (pt) * 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ES2176251T3 (es) * 1993-07-28 2002-12-01 Aventis Pharma Ltd Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
JPH09502170A (ja) * 1993-08-19 1997-03-04 スミスクライン・ビーチャム・コーポレイション フェネチルアミン化合物
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
CA2193725A1 (fr) * 1994-06-24 1996-01-04 David Cavalla Composes derives d'aryles et utilisation de ces composes comme inhibiteurs de l'activite de la phosphodiesterase iv
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
PL332573A1 (en) 1999-09-27
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
DK0934280T3 (da) 2003-07-21
NO991560D0 (no) 1999-03-30
HUP9904063A2 (hu) 2000-09-28
IL129298A0 (en) 2000-02-17
ES2196308T3 (es) 2003-12-16
CN1232456A (zh) 1999-10-20
BG103220A (en) 1999-11-30
CN1106387C (zh) 2003-04-23
SK285878B6 (sk) 2007-10-04
JP3068208B2 (ja) 2000-07-24
JP2000503678A (ja) 2000-03-28
NO312960B1 (no) 2002-07-22
EP0934280A1 (fr) 1999-08-11
NZ334971A (en) 2000-09-29
HUP9904063A3 (en) 2000-11-28
BR9712256B1 (pt) 2011-04-19
BR9712256A (pt) 1999-08-24
EP0934280B1 (fr) 2003-04-09
DE69720757T2 (de) 2004-03-04
CY2380B1 (en) 2004-06-04
EE9900112A (et) 1999-10-15
SI0934280T1 (en) 2003-12-31
CA2267322C (fr) 2007-11-06
KR100520002B1 (ko) 2005-10-13
RU2180902C2 (ru) 2002-03-27
PL194673B1 (pl) 2007-06-29
UA62939C2 (uk) 2004-01-15
AU719561B2 (en) 2000-05-11
US6051718A (en) 2000-04-18
SK34499A3 (en) 2000-04-10
HU225158B1 (en) 2006-07-28
PT934280E (pt) 2003-08-29
WO1998014432A1 (fr) 1998-04-09
AR008875A1 (es) 2000-02-23
MY116980A (en) 2004-04-30
NO991560L (no) 1999-06-02
EE03825B1 (et) 2002-08-15
CZ297474B6 (cs) 2006-12-13
CZ102899A3 (cs) 1999-07-14
HK1020344A1 (en) 2000-04-14
IL129298A (en) 2006-04-10
ATE236884T1 (de) 2003-04-15
CA2267322A1 (fr) 1998-04-09
AU4779297A (en) 1998-04-24
DE69720757D1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
KR100520002B1 (ko) Pde iv 를 억제하는 2-시아노이미노이미다졸 유도체
KR19980703450A (ko) Pde iv 및 사이토킨 억제 활성을 가진 1,3-디하이드로-1-(페닐알케닐)-2h-이미다졸-2-온 유도체
JP4778612B2 (ja) Pdeiv阻害ピリジン誘導体
KR100400159B1 (ko) Pdeiv및사이토킨억제활성을가진1,3-디하이드로-2h-이미다졸-2-온유도체
HK1020344B (en) Pde iv inhibiting 2-cyanoiminoimidazole derivatives
MXPA00009632A (en) Pde iv inhibiting pyridine derivatives
HK1033579B (en) Pde iv inhibiting pyridine derivatives